ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

TILS Tiziana Life Sciences Plc

58.50
0.00 (0.00%)
24 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tiziana Life Sciences Plc LSE:TILS London Ordinary Share GB00BKWNZY55 ORD 3P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 58.50 45.00 60.00 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Tiziana Life Sciences Share Discussion Threads

Showing 12126 to 12149 of 17925 messages
Chat Pages: Latest  489  488  487  486  485  484  483  482  481  480  479  478  Older
DateSubjectAuthorDiscuss
13/1/2021
14:22
Am looking for £2 next stop before Covid trial comes out.
deanmatlazin
13/1/2021
14:19
Reb your one of a kind, US disregards at its own peril. Regeneron has the Cash to buy this for many billions, mark my words. Oh Regeneron is American is it not!
impala391
13/1/2021
14:16
You emphasise my point Tom, I say again the US only take what they want seriously...
rebelwithacause1
13/1/2021
14:13
Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS) said it has hired an industry veteran with experience of successfully developing blockbuster monoclonal antibody products as its chief medical officer.

At Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Dr Neil Graham was “instrumental” in bringing to market Dupixent, a blockbuster monoclonal antibody product for eczema and asthma, taking it from phase I to launch.

During his tenure, he also led the product development for Kevzara, an IL-6R antibody for rheumatoid arthritis, which is now also being used to fight coronavirus (COVID-19) symptoms.

Graham’s experience will be crucial during the clinical evolution of Tiziana candidates Foralumab, a monoclonal antibody (mAB) treatment for autoimmune and inflammatory diseases, Milciclib, for cancer, and TZLS-501, its anti-IL-6 drug.

He hailed as a potential “game-changer” the ability to deliver antibody immuno-therapeutics both orally and nasally, an approach being pioneered with Foralumab.

In a statement, Tiziana chairman and founder, Gabriele Cerrone, said of Graham: “His knowledge and experience at Regeneron in developing blockbuster monoclonal antibody drugs such as Dupixent will be invaluable in developing Foralumab and our anti-IL-6 drug, TZLS-501.”

As well as a 10-year stint at Regeneron, Graham has held roles with drug developers Vertex, Trimeris and Glaxo Welcome and he was also an associate professor at John Hopkins University in the US.

yidarmytom
13/1/2021
13:57
Or the other way Puff, wide disparity between the two listings...Imp the US only take what they want seriously!
rebelwithacause1
13/1/2021
13:48
Looks like the USA will be playing catch up with the UK today looking at pre market.
jpuff
13/1/2021
13:11
glad you are posting andy - you are such a Green Flag bud
yidarmytom
13/1/2021
13:00
NastyDump isInthe making UrsTruly allBuTT o
andymunchkin
13/1/2021
12:01
My cartalk is only to wind up the shorters :)
aberloon2
13/1/2021
11:51
Nasdaq will have to take this seriously now!! aye Reb.
impala391
13/1/2021
11:16
Market obviously likes the new man on the team
ayl30
13/1/2021
10:38
Soon be £2+ and £5 target for reason.Way under value.Brazil update imminent and we also going main market on 21st.
36jay
13/1/2021
10:24
but it's a red flag when bulletin board posts talk of new cars
yidarmytom
13/1/2021
10:21
I have pre-ordered a Lordstown Motors Endurance because I wanted a Truck not a sedan - I spend half my time in the U.S. so didn't want a Tesla - they are everywhere!

Regeneron grew from $3bn to $50bn in short order on the back of a few antibodies.

yidarmytom
13/1/2021
10:13
Yes Tesla great choice fellow genuine investor.
mark0419
13/1/2021
10:11
Relentless buying now..... WowHope small crow is going to be OK with mouldy bread this winter.hehe
mark0419
13/1/2021
10:09
Looking at my TESLA catalogue now.
aberloon2
13/1/2021
10:09
Dr. Graham stated: "I am excited to join Tiziana to help develop its unique monoclonal antibody platform for autoimmune diseases. Tiziana's ability to deliver antibody immunotherapeutics via oral and nasal routes is a potential game-changer for patients and physicians alike".If he can see the potential working for a billion dollar company like Regeneron then that's good enough for me.The credentials are insane.GOOD LUCK TO ALL GENUINE INVESTORS
mark0419
13/1/2021
09:38
Lets see DM...
rebelwithacause1
13/1/2021
09:35
Wonder what boiler room some are associated with and how much do they receive for each negative comment written. So sad. Currently flicking through my BMW new car catalogue. Wonder which one to choose. This has been a dream investment for me. Cheers.
mark0419
13/1/2021
09:32
I am sure Dr Graham can grow this company from a quarter of billion £ to few billions...at least :)
deanmatlazin
13/1/2021
09:27
Lets not get ahead ourselves just yet...the surge was expected in the run-up to main market listing (as my comments stated last Dec) but it won't last!
rebelwithacause1
13/1/2021
09:26
This is looking amazing how did they pull that off...... Like signing Lionel Messi.
mark0419
13/1/2021
09:21
Employing Dr Graham with extensive experience together with Tiziana’s world class drug awaiting to go few trials....sky is the limit where there share price should go up to :)
deanmatlazin
Chat Pages: Latest  489  488  487  486  485  484  483  482  481  480  479  478  Older

Your Recent History

Delayed Upgrade Clock